Development and Validation of the Pediatric Charcot–Marie–Tooth Disease Quality of Life Outcome Measure

Charcot–Marie–Tooth disease (CMT) reduces health‐related quality of life (QOL), especially in children. Defining QOL in pediatric CMT can help physicians monitor disease burden clinically and in trials. We identified items pertaining to QOL in children with CMT and conducted validation studies to develop a pediatric CMT‐specific QOL outcome measure (pCMT‐QOL).

• Publication year

  2020

• Venue

  Annals of Neurology

• Publication date

  2020-11-22

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/ana.25966PMID 33222249PMCID PMC11671102
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A longitudinal study of CMT1A using Rasch analysis based CMT neuropathy and examination scores.

  2020cited by this paper
• Balance impairment in pediatric charcot–marie–tooth disease

  2019cited by this paper
• Gene replacement therapy in a model of Charcot-Marie-Tooth 4C neuropathy

  2019cited by this paper
• Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.

  2019cited by this paper
• The Charcot-Marie-Tooth Functional Outcome Measure (CMT-FOM)

  2018cited by this paper
• The Charcot–Marie–Tooth Health Index: Evaluation of a Patient‐Reported Outcome

  2018cited by this paper
• PMP22 antisense oligonucleotides reverse Charcot-Marie-Tooth disease type 1A features in rodent models

  2017cited by this paper
• Pediatric Charcot-Marie-Tooth disease.

  2015cited by this paper
• Defining disability: development and validation of a mobility-Disability Severity Index (mDSI) in Charcot-Marie-tooth disease

  2014cited by this paper
• Psychometrics evaluation of Charcot‐Marie‐Tooth Neuropathy Score (CMTNSv2) second version, using Rasch analysis

  2014cited by this paper
• CMT subtypes and disease burden in patients enrolled in the Inherited Neuropathies Consortium natural history study: a cross-sectional analysis

  2014cited by this paper
• High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trial.

  2013cited by this paper
• Quality-of-Life Measures in Children With Neurological Conditions

  2012cited by this paper
• Validation of the Charcot–Marie–Tooth disease pediatric scale as an outcome measure of disability

  2012cited by this paper
• Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial

  2011cited by this paper
• Determinants of reduced health-related quality of life in pediatric inherited neuropathies

  2010influential reference
• 168th ENMC International Workshop: outcome measures and clinical trials in Charcot-Marie-Tooth disease (CMT).

  2010cited by this paper
• Quality of Life in Children With Charcot-Marie-Tooth Disease

  2010influential reference
• Quality of life in children with CMT type 1A.

  2009cited by this paper
• Fatigue, reduced sleep quality and restless legs syndrome in Charcot-Marie-Tooth disease: a web-based survey

  2009cited by this paper
• Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia

  2009cited by this paper
• Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.

  2009cited by this paper
• The pediatric quality of life inventory: measuring pediatric health-related quality of life from the perspective of children and their parents.

  2009cited by this paper
• Natural history of CMT1A including QoL: a 2-year prospective study.

  2008cited by this paper
• Factors that influence health-related quality of life in Australian adults with Charcot-Marie-Tooth disease.

  2008cited by this paper
• Severe early-onset axonal neuropathy with homozygous and compound heterozygous MFN2 mutations

  2008cited by this paper
• Oral curcumin mitigates the clinical and neuropathologic phenotype of the Trembler-J mouse: a potential therapy for inherited neuropathy.

  2007cited by this paper
• Autosomal‐recessive and X‐linked forms of hereditary motor and sensory neuropathy in childhood

  2007cited by this paper
• Patient-reported outcomes to support medical product labeling claims: FDA perspective.

  2007cited by this paper
• Antiprogesterone therapy uncouples axonal loss from demyelination in a transgenic rat model of CMT1A neuropathy

  2007cited by this paper
• Health and Quality of Life Outcomes

  2006cited by this paper
• Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

  2006cited by this paper
• Variables influencing quality of life and disability in Charcot Marie Tooth (CMT) patients: Italian multicentre study

  2006cited by this paper
• Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder

  2005cited by this paper
• Psychosocial Issues That Face Patients With Charcot-Marie-Tooth Disease: The Role of Genetic Counseling

  2005cited by this paper
• Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease

  2004cited by this paper
• Measuring health-related quality of life in children: the development of the TACQOL parent form

  2004cited by this paper
• PedsQL 4.0: reliability and validity of the Pediatric Quality of Life Inventory version 4.0 generic core scales in healthy and patient populations.

  2001cited by this paper
• The Child Health Questionnaire in Australia: reliability, validity and population means

  2000cited by this paper
• Canadian-French, German and UK versions of the Child Health Questionnaire: methodology and preliminary item scaling results

  1998cited by this paper
• Minimum skills required by children to complete health-related quality of life instruments for asthma: comparison of measurement properties.

  1997cited by this paper
• SF-36 physical and mental health summary scales : a user's manual

  1994cited by this paper
• The MOS 36‐Item Short‐Form Health Survey (SF‐36): II. Psychometric and Clinical Tests of Validity in Measuring Physical and Mental Health Constructs

  1993cited by this paper
• The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection

  1992cited by this paper
• The MOS 36-Item Short-Form Health Survey (SF-36)

  1992cited by this paper
• THE MOS 36- ITEM SHORT FORM HEALTH SURVEY (SF- 36) CONCEPTUAL FRAMEWORK AND ITEM SELECTION

  1992cited by this paper
• Subjective measures of well-being.

  1976cited by this paper
• An index of factorial simplicity

  1974cited by this paper
• Genetic and clinical aspects of Charcot‐Marie‐Tooth's disease

  1974cited by this paper

• Charcot–Marie–Tooth disease and related neuropathies

  2026cites this paper
• Validation and Reliability of the Thai Pediatric Charcot–Marie–Tooth Quality of Life Outcome Measure

  2025cites this paper
• Designing and Implementing a Web‐Based Platform for Accurate and Reliable Clinical Outcome Measures and Global Certification for Evaluating Charcot–Marie–Tooth disease

  2025cites this paper
• Multicenter Validation of the Charcot-Marie-Tooth Functional Outcome Measure

  2024cites this paper
• Development of a functional outcome measure for riboflavin transporter deficiency

  2024cites this paper
• Parent‐proxy pediatric CMT quality of life outcome measure: Validation of the Italian version

  2024cites this paper
• Validation of the parent‐proxy version of the pediatric Charcot‐Marie‐Tooth disease quality of life instrument for children aged 0–7 years

  2023cites this paper
• Validation of the parent‐proxy pediatric Charcot‐Marie‐Tooth disease quality of life outcome measure

  2023cites this paper
• Trials for Slowly Progressive Neurogenetic Diseases Need Surrogate Endpoints

  2023cites this paper
• Hereditary neuropathy.

  2023cites this paper
• Disease Progression in Charcot–Marie–Tooth Disease Related to MPZ Mutations: A Longitudinal Study

  2022cites this paper
• Quality of life and upper limb disability in Charcot-Marie-Tooth disease: A pilot study

  2022cites this paper
• Validation of the Italian version of the pediatric CMT quality of life outcome measure

  2022cites this paper
• Updated review of therapeutic strategies for Charcot-Marie-Tooth disease and related neuropathies

  2021cites this paper
• Clinical and Genetic Aspects of Childhood-Onset Demyelinating Charcot–Marie–Tooth's Disease in Brazil

  2021cites this paper
• Mechanisms and Treatments in Demyelinating CMT

  2021cites this paper